COVID

CBD News Summary: Canadian Study Finds that CBD May Inhibit the “Pathway” for COVID-19 Infection

The latest news is that CBD may inhibit the “Pathway” for COVID-19 Infection:

  • It has been found in a Canadian study that CBD may inhibit the protein “pathway” that the COVID-19 virus uses to cause infection in human cells.
  • Hemp has been listed as an ineligible product by the USDA for its Coronavirus Food Assistance Program.
  • Two CBD companies have deliberately recalled some of their products.
  • A company has been developed by one of the largest Canadian companies to enter the US hemp-derived CBD trade.

CBD News Stories

  1. Canadian Study: CBD May Inhibit The ‘Pathway’ for COVID-19
  2. Hemp Is Enlisted As Ineligible by USDA  for Coronavirus Food Assistance Program
  3. Two CBD Companies DeliberatelyRevised Products
  4. Aurora Cannabis Enters US CBD Market with Acquisition

Canadian Study: CBD May Inhibit  ‘Pathway’ For COVID-19

Evidence has been found in a  study by Pathway Rx, in partnership with researchers at the University of Lethbridge,  that recommends CBD can hinder the pathway for COVID-19 infection.

According to the researchers, COVID-19 is found to infect human cells through ACE2, an enzyme that is present in “gateway” tissues.

Intestinal, airway, and oral tissues are included in the gateway tissues.

Dr. Igor Kovalchuk, CEO of Pathway Rx, said , in a statement “Angiotensin-converting enzyme 2 (ACE2) has been  believed as a receptor mandatory for the entry of SARS-CoV-2 into human cells by the scientific community.”

The 3D human models of intestinl, airways and oral tissues was used by the researchers to test the effect of high-CBD cannabis extracts on the level of ACE2,  as well as other compounds.

The researchers wrote that they had identified 13  high CBD C. sativa extracts that regulate ACE2 gene expression and ACE2 protein levels.

It was also found that Protein TMPRSS2, necessary for the COVID-19 virus to infect human cells, was also supprssed bu some of the extracts.

Dr. Kovalchuk said, “Our preliminary findings validate further analysis but it’s possible that medical cannabis products could be a safe additional therapy for the treatment of COVID-19.”

It was suggested by the researchers that any powerful treatments could be turned into “trouble-free preventative treatments in the form of throat gargle products and mouthwash for both clinical and at-home use.”

Researchers wrote that every possible  therapeutic opportunity must be considered in the current terrible and rapidly progressing epidemiological situation.

Hemp Is Enlisted As Ineligible Commodity By USDA For Coronavirus Food Assistance Program

In a report on Tuesday, it was announced by the USDA that hemp is not an eligible crop for its coronavirus food assistance program.

According to the report, hemp is disqualified because it is one of several item that has not tolerated a drop of five percent or more in price between January and April.

Other disqualified crops are sheep with age more than two years old, layers/eggs, hard red winter wheat, soft red winter wheat, rye, flax, white wheat, Extra Long Staple cotton, forage crops, feed barley, and tobacco.

Another important warning is also included in the USDA, however.

If the  “strong evidence” supporting the five percent decrease can be provided by the farmer, USDA officials may “review the prohibited items.”

In the start, USDA decided not to reconsider tobacco and hemp; nonetheless, the agency updated its reports within few hours to reconsider the ineligible tobacco and hemp products.

This exclusion was considered “very disappointing” in a post by the US Hemp Roundtable on Twitter.

Jonathan Miller, general counsel for the US Hemp Roundtable, indicated to Marijuana Moment that providing a proof for 5% decrease in hemp prices would be difficult as there is no mature and practical pricing details like for soybeans or corn.

The USDA has been massively associated in the hemp industry.

Currently, the agency has approved state hemp plans, has published guidance on servicing loans for hemp producers, and is working on hemp regulations.

Two CBD Companies Deliberately Revised Products

The CBD companies Summitt Labs and Biota Biosciences are deliberately revising their mass products.

“Batch#730 Lot#K018 of KORE ORGANIC Watermelon CBD Oil Tincture” was revised by Summitt Labs due to high level of lead.

A random testing was done by the Florida Department of Agriculture and Consumer Services which confirmed the level of lead to be 4.7ppm, well above the legal limit.

According to the  revise notice, Summitt Labs  revised this batch of products instantly and pronounced to test a sample of the batch with an ISO-accredited laboratory.

The lead level was found to be 0.5ppm (within the legal limit) in their internal investigation by the state of Florida.

High lead exposure can cause several symptoms, such as vomiting, nausea, pain, and in severe cases, kidney damage.

Summitt Labs mentions they have not received any “complaint, call, or report of any detrimental effect” regarding the product.

Whereas, Biota Biosciences revised their Sterile fundamental products “Curcumin Complex,” “Cannabidiol+Curcumin,” and “Cannabidiol (CBD) Complex,” due to an warning letter of FDA.

The FDA notified the Biota about the medical claims they made about their products which needs to inoculate, such as:

“Fighting the opioid epidemic . . . BIOTA Biosciences manufactures and delivers all-natural substitutes with no side-effects.  BIOTA Sterile CBD Vials are used by the psychiatry, naturopathy, and oncology healthcare professionals.”

It provides instant relief to the patients with symptomatic of inflammatory auto-immune diseases.

There is no enough regulations by Biota for use.

The FDA found Biota’s injectable drugs particularly perturbing because they “go around many of the body’s natural defenses against toxins, toxic ingredients, or dangerous organisms that can cause  serious and deadly conditions such as sepsis or septicemia.”

Biota apologized to his customers in a public letter, “as s a faithful customers with accepted receipt of one of these products, we would like to deliver that the executive and management team at Biota Biosciences take full responsibility for these findings and realize the level of the risk to users by posting these unauthorized claims and intentional use on our website. We extend our sincerest apologies for having exposed you to such risk.”

Biota also declared that they had deleted all the mentioned products from their site, terminated their selling, and forwarded a corrective action plan to the FDA.

Customers were permitted either to keep the products or to have a full refund for returning unused products.

Study Found that CBD may inhibit the “Pathway” for COVID-19 Infection.

Aurora Cannabis Enters US CBD Market With Acquisition

Aurora Cannabis, one of the largest Canadian cannabis companies, is entering into the US CBD market.

It was declared by the Aurora in a press release that it would be receiving Massachusetts-based Reliva, a leading US supplier of hemp-derived CBD, in an all-stock agreement worth approximately US$40 million.

It is expected to close this agreement in June 2020.

Michael Singer, Executive Chairman and Interim CEO of Aurora, said in a statement that Aurora and Reliva would partner together to form an international cannabinoid leader that they believe could deliver robust revenue and profitable development.

The Canadian company has gone through heavy losses and strived to be productive in the past.

However, it is believed by Aurora that their acquisition of Reliva—who carries no mortage and has good profit margins—could  change that rapidly.

Singer said that they had a firm believe that their collaboration with Reliva would create notable long-term profit as Reliva provides them options to grow in hemp-derived CBD internationally.”

Miguel Martin, CEO of Reliva, has has 25 years of experience in the CPG industry; he has also been the president and vice president at numerous large e-cigarette companies.

After this announcement the stock price of Aurora jumped to 33% during after-hours trading.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top